In-vitro activity of three fluoroquinolones, cefotaxime and clindamycin against staphylococci.
The in-vitro activity of three fluoroquinolones (ciprofloxacin, ofloxacin, temafloxacin) against 200 well-defined clinical isolates of staphylococci was investigated. The in-vitro activity of the fluoroquinolones tested was equal, with a strong indication of cross resistance. A clear distribution over two populations of different quinolone susceptibility--"naturally susceptible" and "naturally resistant" strains--could be found in penicillin-resistant, methicillin-susceptible Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus.
Schumacher-Perdreau
F
F
Institute of Medical Microbiology and Hygiene, University of Cologne, Germany.
Peters
G
G
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002439:Cefotaxime / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*; D015363:Quinolones / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D015363:Quinolones; C054745:temafloxacin; D002981:Clindamycin; D002939:Ciprofloxacin; D015242:Ofloxacin; D002439:Cefotaxime